Open AccessHigh Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer
Author(s) -
Dakai Xiao,
Qiuhua Deng,
Dongxu He,
Ying Huang,
Wenchi Liang,
Fengnan Wang,
Huanming Yang
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s325443
Subject(s) - crizotinib , medicine , lung cancer , anaplastic lymphoma kinase , oncology , alk inhibitor , exome sequencing , cancer research , mutation , gene , biology , genetics , malignant pleural effusion
About 20% of patients with ALK -rearranged non-small cell lung cancer (NSCLC) develop acquired resistance to tyrosine kinase inhibitor (TKI) during the first 6 months. This study aimed to examine the molecular mechanisms of early TKI resistance and prognosis in ALK -rearranged NSCLC.